Abstract
Ubiquitin C-terminal hydrolase L1 (UCHL1), a deubiquitinating enzyme, plays a significant role in cancer chemoresistance. This study investigates its impact on breast cancer (BC), finding that upregulated UCHL1 expression is positively associated with chemoresistance and poor prognosis, particularly in HER2+ subtypes. Mechanistically, UCHL1 promotes resistance to Doxorubicin (DOX) by upregulating free fatty acid (FFA) synthesis. Inhibiting UCHL1 restores DOX sensitivity, suggesting it as a potential clinical target for overcoming resistance in HER2+ BC patients.
Introduction
Breast cancer remains a primary cause of cancer-related deaths among women globally. The HER2-positive (HER2+) subtype is notably aggressive and often treated with Doxorubicin (DOX). However, the development of chemoresistance frequently limits the efficacy of this treatment. Recent research has turned toward deubiquitinating enzymes, specifically Ubiquitin C-terminal hydrolase L1 (UCHL1), as potential drivers of this resistance. While UCHL1's role in other malignancies is documented, its specific metabolic influence on breast cancer chemoresistance has remained largely unexplored until now.
Methods and Datasets
The researchers utilized a local cohort of 54 primary breast cancer tissue samples from the Affiliated Suzhou Hospital of Nanjing Medical University for immunohistochemistry (IHC) analysis. To validate these findings on a larger scale, they accessed the Kaplan-Meier Plotter database, analyzing survival data from hundreds of patients. Experimental models included various BC cell lines (e.g., SK-BR-3, BT474) and a specifically developed DOX-resistant line, MCF-7/DOX. Metabolic changes were tracked using gas chromatography–mass spectrometry (GC–MS) to quantify free fatty acids, alongside Western blotting to measure lipogenic enzymes like FASN and ACACA.
Clinical Correlation of UCHL1 and Chemoresistance
Analysis of the clinical samples revealed a stark correlation between UCHL1 levels and treatment response. Patients with high UCHL1 expression (determined by H-score) were significantly more likely to exhibit resistance to DOX-based chemotherapy ($p = 0.0259$). Furthermore, high UCHL1 levels served as a prognostic "red flag," correlating with poorer recurrence-free and distant metastasis-free survival.
As shown in the figure above, the distribution of UCHL1 expression (A) and visual IHC staining (B) highlight the variance in patient tissues. The constituent ratio (C) clearly demonstrates that chemoresistant patients have a much higher proportion of UCHL1-high tumors compared to chemosensitive patients.
Mechanistic Insights: Metabolic Rewiring
The study's most groundbreaking finding is the link between UCHL1 and lipid metabolism. UCHL1 appears to hijack cellular pathways to promote lipogenesis—the creation of fats. Specifically, cancer cells with elevated UCHL1 levels produce higher amounts of free fatty acids (FFAs). These FFAs act as a metabolic shield, providing a survival advantage that enables cells to withstand the cytotoxic effects of Doxorubicin.
Crucially, this resistance is reversible. By using the small-molecule inhibitor LDN-57444 to block UCHL1 activity, the researchers observed a significant decrease in the expression of key enzymes like Fatty Acid Synthase (FASN) and a subsequent restoration of DOX sensitivity in previously resistant cell lines.
Conclusion and Future Outlook
This research identifies UCHL1 as a critical mediator of Doxorubicin resistance in HER2+ breast cancer through the upregulation of fatty acid synthesis. By acting as both a prognostic biomarker and a functional driver of metabolic rewiring, UCHL1 presents a dual opportunity for clinical intervention. Future work focusing on in vivo validation and identifying the specific protein substrates of UCHL1 will be essential to translating these findings into effective combination therapies for patients facing chemoresistant breast cancer.
Summary updated